Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, no association was found between the AR gene and type II androgenetic alopecia in Egyptian women, suggesting it is not a useful biomarker for predisposition.

This study found that the ASLNC168501 pathway has significant potential for restoring hair follicle stem cell function and promoting hair regeneration in androgenetic alopecia by counteracting the AR/miR-128-3p/IGF-1 pathway dysfunction.

This study developed a gas-propelled microneedle patch with puerarin/quercetin nanoparticles, which demonstrated improved hair-regenerating effects in an androgenetic alopecia mouse model by increasing drug delivery, alleviating oxidative stress, promoting angiogenesis, and rejuvenating senescent cells.

5% ET-02 is a more effective and safe treatment for hair loss than current options.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

In this study, researchers developed a promising transdermal agent using Triton X-100-modified polyethyleneimine that successfully delivered genetic material to hair follicle cells in mice, potentially alleviating hair loss due to androgenetic alopecia by promoting cell proliferation and inhibiting apoptosis.

In this study, selective overexpression of androgen receptors in muscle cells increased lean muscle mass and reduced fat mass in transgenic rodents, suggesting a potential target for drug development.

This study found that the small signaling peptide RALF22 plays a key role in root hair growth response to volatile compounds emitted by Penicillium aurantiogriseum through ethylene, auxin, and photosynthesis signaling in Arabidopsis.

This study found that overexpression of the lncRNA AL136131.3 may inhibit hair shaft growth and promote hair follicle apoptosis in androgenetic alopecia by influencing key metabolic pathways.

This study synthesized and verified the structures of Setipiprant's major and minor metabolites, confirming their regio- and enantioselectivity from earlier proposals in a clinical study.

This review discusses androgenetic alopecia and existing treatments, reporting no new clinical results; the authors highlight promising prospects for androgen receptor degrader drugs among therapeutic options.

In this study, Terminalia bellirica extracts promoted hair regrowth in testosterone-induced AGA mice, possibly by inhibiting type II 5α-reductase activity and enhancing the MAPK signaling pathway.

This study identified neprilysin as a potential target of the pharmacological agent arteannuin, which may guide future research into its clinical applications, although experimental verification is needed.

RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.

In this study, researchers characterized the retinal structure and function of the Oat^rhg mouse model of gyrate atrophy, finding localized atrophy without significant retina-wide functional impact, suggesting the model may be useful for testing new treatments using multimodal retinal imaging.

This article discusses the factors driving the platelet-rich plasma market in dermatology and reports no clinical results; it highlights the need for more affordable and accessible treatments.

This letter to the editor discusses patient perspectives on androgenetic alopecia treatment at a tertiary dermatology center in Singapore, though results or specific findings are not reported in the abstract.

This study suggests that androgen receptor CAG polymorphisms may not significantly influence androgenetic alopecia susceptibility in Korean men.

This study developed nanoliposomes embedding AR-PROTAC and NFKBIZ siRNA to target androgen receptors and reduce oxidative stress, which improved the follicular microenvironment and enhanced hair regrowth in androgenetic alopecia, suggesting a promising multi-target therapeutic strategy.

This study identified polymorphisms in HGT-KRTAP7-1 and KRTAP8-1 genes in Argentine llamas that may impact fiber characteristics by altering amino acid residues critical for keratin-associated protein properties.

This study found that contrast enhanced phototrichogram (CE-PTG) significantly improved detection of various hair types and growth stages in androgenetic alopecia compared to standard PTG and was comparable to biopsy analysis.

This study found that the peach gene CTG134, involved in auxin-ethylene interactions, plays a role in hormonal regulation during root hair formation in Arabidopsis and tobacco.

This study found that growth factor cocktail treatment including FGF9, combined with microneedling, significantly improved hair density in androgenetic alopecia patients compared to treatment with regular GFC or normal saline.

The researchers reported that the SAGI PGP procedure resulted in excess weight loss of over 90% in the first year and normalized blood sugar levels without medication among diabetic patients by the first month post-operation.

This study found that Agaricus bisporus-derived β-Glucan particles showed potential as an anticancer, antimicrobial, and antioxidant agent, inducing apoptosis and disrupting mitochondrial membrane potential in cervical cancer HeLa cells.

This study found that serum GPER-1 levels were significantly higher in patients with androgenetic alopecia compared to healthy controls, suggesting a potential role in the condition's pathogenesis, independent of gender.

Hair loss treatment caused more hair loss in a man.

This study, conducted among Egyptians, found a borderline significant association between the Stul polymorphism of the androgen receptor gene and androgenetic alopecia in males, with higher androgen receptor expression in balding scalp areas.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.